JP2008540563A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540563A5 JP2008540563A5 JP2008511366A JP2008511366A JP2008540563A5 JP 2008540563 A5 JP2008540563 A5 JP 2008540563A5 JP 2008511366 A JP2008511366 A JP 2008511366A JP 2008511366 A JP2008511366 A JP 2008511366A JP 2008540563 A5 JP2008540563 A5 JP 2008540563A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- nebulizer
- mutated
- lung
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/127,438 US20050271660A1 (en) | 2002-09-06 | 2005-05-11 | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| PCT/US2006/018269 WO2006122257A2 (en) | 2005-05-11 | 2006-05-10 | Nebulization of monoclonal antibodies for treating pulmonary diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012193985A Division JP2012233013A (ja) | 2005-05-11 | 2012-09-04 | 肺疾患を処置するためのモノクローナル抗体の霧状化 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008540563A JP2008540563A (ja) | 2008-11-20 |
| JP2008540563A5 true JP2008540563A5 (enExample) | 2009-06-04 |
Family
ID=37054603
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008511366A Withdrawn JP2008540563A (ja) | 2005-05-11 | 2006-05-10 | 肺疾患を処置するためのモノクローナル抗体の霧状化 |
| JP2012193985A Pending JP2012233013A (ja) | 2005-05-11 | 2012-09-04 | 肺疾患を処置するためのモノクローナル抗体の霧状化 |
| JP2014125985A Pending JP2014169332A (ja) | 2005-05-11 | 2014-06-19 | 肺疾患を処置するためのモノクローナル抗体の霧状化 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012193985A Pending JP2012233013A (ja) | 2005-05-11 | 2012-09-04 | 肺疾患を処置するためのモノクローナル抗体の霧状化 |
| JP2014125985A Pending JP2014169332A (ja) | 2005-05-11 | 2014-06-19 | 肺疾患を処置するためのモノクローナル抗体の霧状化 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US20050271660A1 (enExample) |
| EP (1) | EP1881993A2 (enExample) |
| JP (3) | JP2008540563A (enExample) |
| AU (1) | AU2006243994B2 (enExample) |
| CA (1) | CA2608195A1 (enExample) |
| NZ (2) | NZ582627A (enExample) |
| WO (1) | WO2006122257A2 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US9415102B2 (en) * | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| EP1545611B1 (en) * | 2002-09-06 | 2016-11-09 | Alexion Pharmaceuticals, Inc. | Method of treatment of asthma using antibodies to complement component c5 |
| US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| KR101137052B1 (ko) * | 2003-11-17 | 2012-04-24 | 노바르티스 아게 | 인공호흡기 회로에 대한 에어로졸의 효과적인 주입 |
| BRPI0506629A (pt) | 2004-02-10 | 2007-05-02 | Univ Colorado | inibição do fator b, a via alternativa do sistema complemento e métodos relacionados |
| US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CN103505728A (zh) | 2005-05-26 | 2014-01-15 | 科罗拉多大学评议会法人机构 | 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制 |
| US20070191262A1 (en) * | 2005-11-15 | 2007-08-16 | University Of Iowa Research Foundation | Cancer Therapy and Prevention Based on Modulation of Complement activity |
| HUE066795T2 (hu) | 2006-03-15 | 2024-09-28 | Alexion Pharma Inc | Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral |
| EP2061501B1 (en) * | 2006-09-08 | 2015-04-08 | Volution Immuno Pharmaceuticals SA | Method of treating respiratory disorders |
| US8312879B2 (en) * | 2006-10-16 | 2012-11-20 | General Electric Company | Method and apparatus for airway compensation control |
| WO2008140653A2 (en) | 2007-03-14 | 2008-11-20 | Taligen Therapeutics, Inc. | Humaneered anti-factor b antibody |
| KR101616758B1 (ko) * | 2007-12-26 | 2016-04-29 | 젠코어 인코포레이티드 | ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체 |
| CA2718588A1 (en) * | 2008-02-19 | 2009-08-27 | The Trustees Of The University Of Pennsylvania | Complement inhibitors as therapeutic agents for treatment of cancer |
| US12492253B1 (en) | 2008-02-25 | 2025-12-09 | Xencor, Inc. | Anti-human C5 antibodies |
| US20220281964A1 (en) * | 2008-02-25 | 2022-09-08 | Xencor, Inc. | Fc VARIANTS WITH ALTERED BINDING TO FcRn |
| JP6223659B2 (ja) | 2008-11-10 | 2017-11-01 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体関連障害を処置するための方法および組成物 |
| ES2701649T3 (es) * | 2009-01-14 | 2019-02-25 | Ablynx Nv | Administración pulmonar de dominios variables individuales de inmunoglobulina y constructos de los mismos |
| GB0904214D0 (en) * | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
| US9187568B2 (en) | 2009-05-07 | 2015-11-17 | Stallergenes S.A. | Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route |
| KR20100123240A (ko) * | 2009-05-15 | 2010-11-24 | 포항공과대학교 산학협력단 | 호흡기 염증성 질환의 치료 또는 예방을 위한 호흡기내 투여용 약학 제제 및 상기 질환의 치료 또는 예방 방법 |
| NZ597259A (en) | 2009-06-23 | 2014-04-30 | Alexion Pharma Inc | Bispecific antibodies that bind to complement proteins |
| JP5871798B2 (ja) | 2009-07-02 | 2016-03-01 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | 肝再生を刺激する方法 |
| JP6012473B2 (ja) | 2010-01-11 | 2016-10-25 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー |
| SI2533761T1 (sl) | 2010-02-11 | 2019-08-30 | Ablynx N.V. | Postopki in sestavki za pripravo aerosolov |
| AU2011245117B2 (en) | 2010-04-30 | 2015-03-12 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies and methods for using the antibodies |
| BR112012033119A2 (pt) | 2010-06-22 | 2016-10-25 | Univ Colorado Regents | anticorpos para o fragamento c3d do componente do complemento 3. |
| US8758824B2 (en) * | 2010-08-30 | 2014-06-24 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
| EP4008326A1 (en) | 2010-09-29 | 2022-06-08 | Pulmatrix Operating Company, Inc. | Monovalent metal cation dry powders for inhalation |
| KR102149028B1 (ko) | 2012-02-20 | 2020-08-27 | 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) | 인간 보체 c5에 결합하는 폴리펩티드 |
| TW201400499A (zh) * | 2012-03-12 | 2014-01-01 | Revo Biolog Inc | 抗凝血酶用於治療妊娠毒血症之用途 |
| US9803005B2 (en) | 2012-05-24 | 2017-10-31 | Alexion Pharmaceuticals, Inc. | Humaneered anti-factor B antibody |
| CN104884080A (zh) | 2012-08-03 | 2015-09-02 | Lfb美国股份有限公司 | 抗凝血酶在体外膜式氧合中的用途 |
| WO2014066744A2 (en) | 2012-10-25 | 2014-05-01 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
| ES2912396T3 (es) | 2012-11-02 | 2022-05-25 | Bioverativ Usa Inc | Anticuerpos anti-C1s del complemento y uso de los mismos |
| US20140170158A1 (en) * | 2012-12-17 | 2014-06-19 | The Johns Hopkins University | Compositions and methods for treating or preventing lung diseases |
| JP6505079B2 (ja) | 2013-03-29 | 2019-04-24 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 |
| KR20150135328A (ko) | 2013-04-01 | 2015-12-02 | 풀매트릭스 인코퍼레이티드 | 티오트로피움 건조 분말 |
| AU2014306002B2 (en) | 2013-08-07 | 2017-05-25 | Alexion Pharmaceuticals, Inc. | Atypical hemolytic uremic syndrome (aHUS) biomarker proteins |
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| TWI750108B (zh) | 2014-04-03 | 2021-12-21 | 瑞士商Ｃｓｌ貝林股份有限公司 | 免疫球蛋白之霧化 |
| JP6532034B2 (ja) * | 2015-03-24 | 2019-06-19 | 学校法人関西医科大学 | 鼻腔抵抗の測定方法、鼻腔抵抗及び肺気道抵抗の測定方法及び該方法の実施に用いる測定装置 |
| EP4212175A1 (en) | 2015-04-06 | 2023-07-19 | Bioverativ USA Inc. | Humanized anti-c1s antibodies and methods of use thereof |
| CA2986957A1 (en) | 2015-06-03 | 2016-12-08 | Children's Hospital Medical Center | Compositions and methods for treating neonatal biliary atresia |
| CA3024618A1 (en) | 2016-05-27 | 2017-11-30 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| IL263481B2 (en) | 2016-06-14 | 2024-06-01 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
| IL326479A (en) | 2016-10-12 | 2026-04-01 | Bioverativ Usa Inc | Anti-c1s antibodies and methods of use thereof |
| US11220544B2 (en) | 2017-07-14 | 2022-01-11 | Cytomx Therapeutics, Inc. | Anti-CD166 antibodies and uses thereof |
| ES2965486T3 (es) | 2017-07-27 | 2024-04-15 | Alexion Pharma Inc | Formulaciones de anticuerpos anti-C5 de alta concentración |
| JP7518764B2 (ja) | 2017-10-26 | 2024-07-18 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与 |
| AU2018383751B2 (en) | 2017-12-13 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibody combinations and uses thereof |
| US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
| EP3802593B1 (en) | 2018-05-31 | 2024-09-11 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
| EP3802603A1 (en) | 2018-06-04 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients |
| JP7538723B2 (ja) | 2018-06-28 | 2024-08-22 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗ｃ５抗体の産生方法 |
| WO2020092546A1 (en) * | 2018-10-30 | 2020-05-07 | Alexion Pharmaceuticals, Inc. | Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions |
| US12240893B2 (en) | 2018-10-30 | 2025-03-04 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) |
| KR20250116790A (ko) | 2018-12-12 | 2025-08-01 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 및 car-t 세포 및 사용 방법 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| CA3176425A1 (en) | 2020-04-24 | 2021-10-28 | Millennium Pharmaceuticals, Inc. | Anti-cd19 antibodies and uses thereof |
| WO2021237109A1 (en) | 2020-05-22 | 2021-11-25 | Trailhead Biosystems Inc. | Combination therapy for treatment of viral infections |
| MX2022015586A (es) | 2020-06-12 | 2023-03-15 | Nkarta Inc | Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70. |
| CN116194478A (zh) | 2020-06-24 | 2023-05-30 | 阿雷克森制药公司 | 皮下（sc）施用抗c5抗体治疗补体相关病症 |
| JP7829595B2 (ja) | 2021-04-09 | 2026-03-13 | 武田薬品工業株式会社 | 補体因子ｄを標的とする抗体及びその使用 |
| PE20241789A1 (es) | 2021-04-26 | 2024-09-06 | Millennium Pharm Inc | Anticuerpos anti-clec12a y usos de los mismos |
| AU2022266583A1 (en) | 2021-04-26 | 2023-10-19 | Millennium Pharmaceuticals, Inc. | Anti-adgre2 antibodies and uses thereof |
| AU2022372894A1 (en) | 2021-10-20 | 2024-04-18 | Takeda Pharmaceutical Company Limited | Compositions targeting bcma and methods of use thereof |
| EP4482872A4 (en) * | 2022-03-07 | 2026-03-18 | Nkarta Inc | Multiplex gene-edited cells for CD70-led cancer immunotherapy |
| EP4507720A1 (en) | 2022-04-14 | 2025-02-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections |
| MA71249A (fr) | 2022-06-24 | 2025-04-30 | Bioverativ Usa Inc. | Méthodes de traitement de maladies médiées par complément |
| CN117100857B (zh) * | 2023-08-15 | 2024-09-10 | 福建医科大学附属协和医院 | 一种抗体金纳米笼载药系统、制备方法和用途 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4228795A (en) * | 1977-03-08 | 1980-10-21 | Babington Robert S | Apparatus for producing finely divided liquid spray |
| WO1991016074A1 (en) * | 1990-04-19 | 1991-10-31 | Medimmune, Inc. | Administration of monoclonal antibodies against respiratory viruses |
| EP0539522B1 (en) * | 1990-07-19 | 1998-12-30 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Improved immunotherapeutic method of preventing or treating viral respiratory tract disease |
| US5871734A (en) * | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
| DE69328098T2 (de) | 1992-06-24 | 2000-08-24 | Adprotech Plc, Royston | Lösliche derivate des complement type-rezeptors (cr1) |
| US5614370A (en) * | 1994-03-18 | 1997-03-25 | Merck & Co., Inc. | Assay to identify human C5a antagonists and agonists |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US20010036650A1 (en) * | 1994-08-16 | 2001-11-01 | Human Genome Sciences, Inc. | C5a receptor |
| AU3729295A (en) | 1994-09-23 | 1996-04-09 | Alexion Pharmaceuticals, Inc. | Methods for the treatment of inflammatory joint disease |
| US5728844A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
| CN1230178A (zh) * | 1996-09-10 | 1999-09-29 | 麦地诺克斯公司 | 含聚二硫代氨基甲酸酯的大分子和其用于治疗和诊断应用的用途 |
| JP2001503406A (ja) | 1996-10-28 | 2001-03-13 | ファーマーク、ニーダーランド、ベスローテン、フェンノートシャップ | 医薬組成物 |
| US7070799B1 (en) * | 1998-02-10 | 2006-07-04 | Generex Pharmaceuticals, Inc. | Method for administering insulin to the buccal region |
| US6956107B2 (en) * | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
| US20020182260A1 (en) * | 1998-05-29 | 2002-12-05 | Cellegy Pharmaceuticals, Inc. | Anti-inflammatory agents and methods for their preparation and use |
| US6093743A (en) * | 1998-06-23 | 2000-07-25 | Medinox Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| IL141155A0 (en) * | 1998-07-30 | 2002-02-10 | Human Rt | Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin |
| US6280994B1 (en) * | 1998-11-25 | 2001-08-28 | Zymogenetics, Inc. | Zace 1: a human metalloenzyme |
| US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US7109299B1 (en) * | 1999-12-16 | 2006-09-19 | Affymax, Inc. | Peptides and compounds that bind to the IL-5 receptor |
| CZ20022413A3 (cs) * | 2000-01-31 | 2003-08-13 | Pfizer Products Inc. | Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4 |
| SK12942002A3 (sk) * | 2000-02-10 | 2003-05-02 | Abbott Laboratories | Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia |
| US6998468B2 (en) * | 2000-03-23 | 2006-02-14 | Tanox, Inc. | Anti-C2/C2a inhibitors of complement activation |
| US6926898B2 (en) * | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7879328B2 (en) * | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| EP1349874A2 (en) * | 2000-06-21 | 2003-10-08 | ZymoGenetics, Inc. | Peptide and polypeptide inhibitors of complement c1s |
| PE20020132A1 (es) * | 2000-06-29 | 2002-03-04 | Abbott Lab | Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos |
| EP1345968A2 (en) * | 2000-12-28 | 2003-09-24 | Altus Biologics Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| US7795494B2 (en) * | 2001-03-22 | 2010-09-14 | Abbott Laboratories | Transgenic mice expressing antibodies specific for genes of interest and uses thereof |
| US8178098B2 (en) * | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| CA2479212A1 (en) * | 2002-03-15 | 2003-09-25 | Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
| WO2003084524A1 (en) * | 2002-03-29 | 2003-10-16 | Neurogen Corporation | Combination therapy for the treatment of conditions with pathogenic inflammatory components |
| US20040131614A1 (en) | 2002-07-19 | 2004-07-08 | Abbott Biotechnology Ltd. | Treatment of pulmonary disorders using TNFalpha inhibitor |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| EP1545611B1 (en) | 2002-09-06 | 2016-11-09 | Alexion Pharmaceuticals, Inc. | Method of treatment of asthma using antibodies to complement component c5 |
| US20030124139A1 (en) * | 2002-11-20 | 2003-07-03 | Irina Esikova | Compositions and methods for stabilizing biological molecules upon lyophilization |
| US7361339B2 (en) * | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
| CN103040732B (zh) * | 2003-02-10 | 2015-04-01 | 伊兰药品公司 | 免疫球蛋白制剂及其制备方法 |
| US20050026881A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| JP2009525986A (ja) * | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| HUE066795T2 (hu) | 2006-03-15 | 2024-09-28 | Alexion Pharma Inc | Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral |
| JP5419709B2 (ja) * | 2007-01-09 | 2014-02-19 | ワイス・エルエルシー | 抗ｉｌ−１３抗体製剤およびその使用 |
| JP4538514B2 (ja) | 2008-07-30 | 2010-09-08 | シャープ株式会社 | 画像圧縮方法、画像圧縮装置、画像形成装置、コンピュータプログラム及び記録媒体 |
| JP6223659B2 (ja) | 2008-11-10 | 2017-11-01 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体関連障害を処置するための方法および組成物 |
| US20100278822A1 (en) | 2009-05-04 | 2010-11-04 | Abbott Biotechnology, Ltd. | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
-
2005
- 2005-05-11 US US11/127,438 patent/US20050271660A1/en not_active Abandoned
-
2006
- 2006-05-10 CA CA002608195A patent/CA2608195A1/en not_active Abandoned
- 2006-05-10 JP JP2008511366A patent/JP2008540563A/ja not_active Withdrawn
- 2006-05-10 EP EP06759586A patent/EP1881993A2/en not_active Withdrawn
- 2006-05-10 WO PCT/US2006/018269 patent/WO2006122257A2/en not_active Ceased
- 2006-05-10 NZ NZ582627A patent/NZ582627A/en unknown
- 2006-05-10 AU AU2006243994A patent/AU2006243994B2/en not_active Ceased
- 2006-05-10 NZ NZ563509A patent/NZ563509A/en not_active IP Right Cessation
-
2012
- 2012-09-04 JP JP2012193985A patent/JP2012233013A/ja active Pending
-
2014
- 2014-06-19 JP JP2014125985A patent/JP2014169332A/ja active Pending
-
2017
- 2017-08-11 US US15/675,074 patent/US10125191B2/en not_active Expired - Lifetime
-
2018
- 2018-10-04 US US16/152,235 patent/US10479828B2/en not_active Expired - Lifetime
-
2019
- 2019-10-09 US US16/597,040 patent/US10927166B2/en not_active Expired - Lifetime
-
2021
- 2021-01-19 US US17/152,054 patent/US20210214427A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012528200A5 (enExample) | ||
| US10479828B2 (en) | Compositions comprising an anti-C5 antibody | |
| JP2012528792A5 (enExample) | ||
| HRP20130835T1 (hr) | Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru | |
| JP2007520508A5 (enExample) | ||
| RU2017144619A (ru) | Катионы одновалентных металлов сухих порошков для ингаляций | |
| HRP20220919T3 (hr) | Sastav za inhalaciju koji sadrži aklidinij za liječenje kronične opstruktivne bolesti pluća | |
| JP2007522229A5 (enExample) | ||
| RU2006132036A (ru) | Комбинация и фармацевтический препарат для лечения аллергий и заболеваний дыхательных путей | |
| JP2014510064A5 (enExample) | ||
| HRP20050570A2 (en) | Powdered medicament for inhalation comprising a tiotropium salt and salmetrol xinafoate | |
| JP2005532988A5 (enExample) | ||
| JP2007528409A5 (enExample) | ||
| JP2019528316A5 (enExample) | ||
| JP2007527430A5 (enExample) | ||
| CA2558426A1 (en) | Formulations decreasing particle exhalation | |
| JP2020023536A (ja) | Ｃｏｐｄの治療のためのフォルモテロール及びブデソニドの組み合わせ | |
| CN115768402A (zh) | 用于治疗急性肺损伤的5-氨基-2,3-二氢-1,4-酞嗪二酮 | |
| HRP20160630T1 (hr) | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata | |
| KR20220137051A (ko) | 염증성 폐질환의 흡입치료용 5-아미노-2,3-디히드로-1,4-프탈라진디온 | |
| US20130125882A1 (en) | Method and composition for treating asthma and copd | |
| Dongare et al. | An overview of recently published patents on pulmonary drug delivery devices | |
| JP2023524064A5 (enExample) | ||
| US20130104881A1 (en) | Stabilized Metered Dose Inhaler | |
| Terzano | Metered dose inhalers and spacer devices |